GSK-3 and BCL-XL Inhibition Mitigates the Competitive Advantage of APC-Mutant Colorectal Cancer Cells

Using multiple human and murine CRC models, researchers revealed that GSK-3 inhibition strongly sensitized to BH3 mimetic-induced killing.